Cadherin-11 Inhibitors to Treat Poor Prognosis Cancers

Reference #: 2009-009

OTC Contact: Ruchika Nijhara, Ph.D., MBA, CLP (Directory Information | Send a Message)

Description

Cadherin-11, a mesenchymal cadherin associated with basal-like breast cancers and invasive cells but not expressed in normal epithelia, aligns with clinical outcome in poor prognosis cancers. The present invention describes novel compounds that inhibit Cadherin-11 and their use as potential therapeutics for poor prognosis carcinomas.
Applications

Potential therapeutics for breast cancer, prostate cancer, renal cancer, multiple myeloma, glioblastoma.

Advantages

Targeting cadherin-11 represent a novel approach to treating and diagnosing aggressive cancers
The compounds are specific for cadherin-11-expressing cells that proliferate in difficult to treat, poor prognosis cancers
There was no cytotoxicity observed at compound concentrations significantly above concentrations that inhibited tumor cell proliferation
No cross reaction with other Cadherins

Stage of Development

A lead compound has been evaluated in a breast cancer model. Preliminary studies have been done to validate the target for glioblastoma multiforme (GBM). The inhibitor demonstrated high specificity for only Cadherin-11 expressing cells.

Inventors

Milton L Brown, Stephen Byers, Sivanesan Dakshanamurthy and Jaime Guidry

Patent Status

Applications are pending